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Abstract
Background: Hematopoietic stem cell transplantation is being increasingly used in cancer therapy.
Diffuse alveolar hemorrhage, an early complication of stem cell transplant, results from bacterial,
viral and fungal infections, coagulopathy, and engraftment syndrome, or can be idiopathic. Diffuse
alveolar hemorrhage associated with Strongyloides stercoralis hyperinfection in stem cell
transplant patients has been rarely reported.
Case presentation: We describe an unusual cause of alveolar hemorrhage post hematopoietic
stem cell transplant due to Strongyloides hyperinfection. Therapy with parenteral ivermectin and
thiabendazole was initiated but the patient deteriorated and died of respiratory failure and septic
shock.
Conclusion: Strongyloides stercoralis hyperinfection is an unusual cause of alveolar hemorrhage
early after hematopoietic stem cell transplant with very high mortality.
Background
Hematopoietic Stem Cell Transplantation (HSCT) is
being widely used as an adjunct to conventional chemo-
radiotherapy for many hematologic and solid malignan-
cies. Diffuse alveolar hemorrhage (DAH) in this setting
can occur due to bacterial, viral and fungal infections,
coagulopathy, cardiac causes, graft versus host disease
(GVHD), drug and radiation toxicity, or it can be idio-
pathic. DAH associated with Strongyloides stercoralis
hyperinfection in stem cell transplant patients has been
rarely reported. We present an interesting case of Strongy-
loides hyperinfection syndrome manifesting as alveolar
hemorrhage and gram negative septicemia. A brief review
of literature on this topic is also presented.
Case presentation
A 52-year old Puerto Rican male presented with acute
onset nausea, vomiting, and abdominal pain 24 days after
autologous Hematopoietic Stem Cell Transplantation
(HSCT) for recurrent stage advanced follicular lym-
phoma.
The lymphoma was diagnosed 7 years prior to transplant,
and was treated with different chemotherapy agents,
including Cyclophosphamide, doxorubicin, vincristine,
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prednisone (CHOP regimen) and rituximab. Following
relapse, he underwent autologous HSCT following a con-
ditioning regimen with carmustine (BCNU), etoposide,
adriamycin, and melphalan (BEAM). Neutrophil engraft-
ment occurred on day nine. Antimicrobial prophylaxis
included valacyclovir, fluconazole, levofloxacin, and tri-
methoprim-sulfamethoxazole. The patient was not taking
steroids or other immunosuppressive medicines at this
time.
Past medical and social history was unremarkable. There
was no significant occupational exposure history. Patient
was noted to have elevated eosinophil count (17% eosi-
nophils; absolute count 0.970 × 109/L) on several occa-
sions, three months prior to the transplant.
On physical examination, his temperature was 37.7°C,
heart rate 85/min, respiratory rate 16/min, blood pressure
110/66 mm Hg, and pulse oximetry 96% on room air. The
respiratory, cardiovascular and abdominal examination
was normal.
The white blood cell count was 7.2 × 109/L (67% neu-
trophils, 18% bands, 5% lymphocytes, 7% monocytes,
2% metamyelocytes, and 1% eosinophils), hemoglobin
11.6 g/dL, platelets 25 × 109/L. Serum chemistry was nor-
mal.
The patient underwent esophagogastroduodenoscopy
(EGD) with duodenal biopsy for persistent nausea and
vomiting. The biopsy showed active inflammation, larval
forms of Strongyloides stercoralis (Figure 1) and stromal
cells with rare cytomegalovirus inclusions. Stool micros-
copy for ova and parasites was negative. Intra venous
immune globulin (IVIG), Ganciclovir, Foscarnet, Ivermec-
tin 15 mg daily and thiabendazole 3 gm daily were started
with relief of symptoms within three days.
Ten days later, the patient developed dyspnea, fever, and
hypoxia. Bilateral crackles were noted on lung ausculta-
tion. His clinical status deteriorated rapidly developing
hypotension and respiratory failure.
While on mechanical ventilation with 100% oxygen, pH
was 7.45; pCO2 33 mm Hg and pO2 120 mm Hg. Throm-
bocytopenia, anemia, and neutrophilia were noted (Table
1). The chest x-ray showed diffuse airspace disease (Figure
2). Echocardiogram was normal. Therapy with Mero-
penem, gentamicin, and vancomycin was initiated. Blood
cultures later grew Klebsiella pneumoniae. Vancomycin
Table 1: Laboratory data at the onset of respiratory distress.
Hemoglobin (gm/dl) 7.8
Hematocrit (%) 22.9
WBC (*109/L) 8.4
Neutrophils (%) 92
Lymphocytes (%) 6
Monocytes (%) 2
Eosinophils (%) 0
Platelet (*109/L) 36
BUN (mg/dl) 28
Creatinine (mg/dl) 0.8
PT (seconds) 12.9
PTT (seconds) 22.9
INR 1.31
HIV Negative
HBV Negative
HCV Negative
RPR Negative
Duodenal biopsy showing Strongyloides stercoralis within  the glandular cells of the mucosa (marked with solid arrows) Figure 1
Duodenal biopsy showing Strongyloides stercoralis within 
the glandular cells of the mucosa (marked with solid arrows). 
The underlying lamina propria showed abundant neutrophils, 
eosinophils and chronic inflammatory cells. Hematoxylin and 
eosin stain; 200×.BMC Cancer 2006, 6:87 http://www.biomedcentral.com/1471-2407/6/87
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was discontinued, while meropenem and gentamicin
were continued with clinical improvement leading to
extubation in four days.
Ten days later, he was reintubated for recurrent respiratory
failure and ventilatory support using BiLevel mode was
provided. Bronchoscopy with bronchoalveolar lavage
(BAL) was suggestive of diffuse alveolar hemorrhage
(DAH). High dose parenteral steroids were initiated.
The BAL fluid showed multiple larval forms of Strongy-
loides stercoralis (Figure 3), 90% hemosiderin laden mac-
rophages and later grew Klebsiella pneumoniae. The
steroids were discontinued and patient was started on
intravenous Ivermectin.
His pulmonary status continued to deteriorate. The
patient developed pneumothorax and subcutaneous
emphysema, and died of progressive respiratory failure
and septic shock 14 days later.
Discussion
Diffuse alveolar hemorrhage syndrome is characterized by
respiratory compromise, diffuse alveolar infiltrates and
progressively bloody BAL in a post-HSCT setting. The
pathogenesis of DAH syndrome is unknown. The causes
of alveolar hemorrhage in post-transplant patients
include bacterial, fungal and viral pneumonia, coagulop-
athy, cardiac dysfunction, radiation or drug toxicity,
engraftment syndrome, and idiopathic DAH syndrome.
The intestinal nematode, Strongyloides stercoralis is rarely
Antero-posterior view of the chest x-ray, showing bilateral diffuse alveolar opacities Figure 2
Antero-posterior view of the chest x-ray, showing bilateral diffuse alveolar opacities.BMC Cancer 2006, 6:87 http://www.biomedcentral.com/1471-2407/6/87
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reported in association with alveolar hemorrhage in HSCT
recipients [1,2].
Strongyloidiasis is endemic in parts of Asia, South Amer-
ica, Europe, and Southeastern United States [2]. The infec-
tion is usually asymptomatic and confined to the
intestinal tract. After penetrating the skin, the filariform
larva enters the blood stream and is transported to the
lungs. The life cycle involves migration up the respiratory
tract, followed by swallowing into the gastrointestinal
tract. Maturation and reproduction in the small intestine
results in the formation of rhabditiform and filariform lar-
vae. Filariform larvae penetrate the intestinal wall or peri-
anal skin causing autoinfection. When cell mediated
immunity is suppressed, the parasite proliferates and
develops a large burden of the infective filariform larvae
which penetrate the intestinal mucosa and disseminate
through the blood stream resulting in hyperinfection.
During penetration of the intestinal epithelium, enteral
bacteria (usually gram negative coliforms) disseminate
systemically. This can lead to gram negative sepsis, a com-
mon and potentially serious complication of Strongy-
loides hyperinfection syndrome. Other pulmonary
complications that can occur include lung abscess and
ARDS [3].
Eosinopenia post HSCT may be important in the genesis
of hyperinfection as eosinophils are a fundamental com-
ponent of the immune response to parasitic infections.
Mechanical destruction of pulmonary capillaries by the
larvae, cytotoxic chemokines released by the parasites,
influx of inflammatory cells and severe endothelial
inflammation that occurs in the periengraftment period
may all contribute to the resultant alveolar hemorrhage.
During hyperinfection, pathologic findings include a
mixed cellular infiltrate of lymphocytes, macrophages,
and neutrophils within the alveolar septal walls associ-
ated with alveolar, interstitial, and intra-vascular larvae
[4].
Strongyloides hyperinfection after solid organ transplan-
tation usually coincides with steroid use for graft rejection
and manifests between 1–3 months post-transplant. Pro-
found immunosuppression during HSCT may be respon-
sible for its earlier presentation post HSCT.
Strongyloides hyperinfection has a mortality exceeding
80% [5] and eradication of strongyloides prior to HSCT
has been reported to improve outcome [6]. Screening of
patients from endemic and high prevalence regions cou-
pled with appropriate treatment prior to HSCT could
avoid a potentially fatal outcome. The optimal screening
strategy is controversial. Seventy five percent of individu-
als with strongyloides infection manifest eosinophilia [7].
The prevalence of eosinophilia in immunocompromised
patients with chronic strongyloidiasis is less than 20%,
making this a poor screening test. Our patient did have
persistent eosinophilia prior to the transplant. Examina-
tion of >3 stool samples for direct identification of Strong-
yloides larval forms has a sensitivity of 60–70%, and this
may even be higher among immunocompromised
patients. A positive ELISA test is accurate in 97% of the
cases with a negative predictive value of 95% in patients
from endemic areas [8]. Given the dreadful outcomes
associated with strongyloides hyperinfection following
HSCT, screening with peripheral eosinophil counts and a
strongyloides ELISA along with stool examination for
confirmation may be warranted prior to HSCT. Significant
eosinophilia before transplant may mandate workup to
rule out infections associated with it.
Ivermectin (150–200 µg/kg/d) is the drug of choice, the
alternative being thiabendazole (50 mg/kg/d, maximum
3.0 g/d) [9]. There are currently no guidelines for the treat-
ment of strongyloides hyperinfection in the immunosup-
pressed patients. Whether combination treatment is better
than ivermectin or thiabendazole alone is not known.
High dose steroids can exacerbate the Strongyloides
hyperinfection syndrome.
Conclusion
Strongyloides stercoralis hyperinfection is a possible
cause of alveolar hemorrhage early after HSCT. A high
index of suspicion, pre-transplant screening, and aggres-
sive treatment in patients from endemic areas may
improve outcome. Further studies are needed to deter-
Bronchoalveolar lavage showing larval forms of Strongyloides  (stained pink) in a background of many hemosiderin laden  macrophages (stained blue and marked with solid arrows) Figure 3
Bronchoalveolar lavage showing larval forms of Strongyloides 
(stained pink) in a background of many hemosiderin laden 
macrophages (stained blue and marked with solid arrows). 
Prussian blue stain for iron; 200×. Stains for fungus and Pneu-
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mine the role of parenteral Ivermectin and combination
treatment with Ivermectin and Thiabendazole for treat-
ment of disseminated strongyloidiasis.
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